1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €3.45 (+0.58%). The median is €3.45 (+0.58%).
| Buy |
3 |
| Hold |
5 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 4.38K | 99.71% |
| Gross profit | 4.38K | 99.71% |
| Net profit | -6.76M | 6.87% |
| EBITDA | -6.61M | 5.09% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.44M |
Number of shares | 1.92M |
52-week high/low | €6.22 - €2.70 |
| Dividends | No |
Beta | 1.08 |
P/E ratio | -0.24 |
PEG ratio | 0.00 |
P/B ratio | 0.52 |
P/S ratio | 1.59 |
Company profile
| Name | Bolt Biotherapeutics |
| CEO | William Quinn |
| Headquarters | Redwood City,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 23 |
Discover assets
Shareholders of Bolt Biotherapeutics also invest in the following assets
